Background
Phase II randomized trial (ECOG-ACRIN E3311). N=511 enrolled, 359 eligible/treated, p16-positive (HPV+) locally advanced oropharyngeal SCC (stage III–IVa, AJCC 7th). Primary transoral surgery (TOS) at 27 credentialed sites, 2013–2017. Adjuvant therapy assigned by pathologic risk: low risk (close/negative margins, no ECE, ≤2 LN) = observation; intermediate risk = randomized to IMRT 50 Gy or 60 Gy; high risk (ECE or positive margins) = 66 Gy + weekly cisplatin.
Interventions and follow up
Arm A: TOS + observation (low risk, n=38 eligible)
Arm B: TOS + IMRT 50 Gy (intermediate risk, n=100)
Arm C: TOS + IMRT 60 Gy (intermediate risk, n=108)
Arm D: TOS + 66 Gy + cisplatin weekly (high risk, n=113)
Primary endpoint: 2-year PFS in intermediate-risk arm B (50 Gy); multi-institutional TOS feasibility
mFollow up: 35.2 month
Arm B: TOS + IMRT 50 Gy (intermediate risk, n=100)
Arm C: TOS + IMRT 60 Gy (intermediate risk, n=108)
Arm D: TOS + 66 Gy + cisplatin weekly (high risk, n=113)
Primary endpoint: 2-year PFS in intermediate-risk arm B (50 Gy); multi-institutional TOS feasibility
mFollow up: 35.2 month
Results
2-year PFS Arm A: 96.9% (90% CI 91.9–100)
2-year PFS Arm B (50 Gy): 94.9% (90% CI 91.3–98.6)
2-year PFS Arm C (60 Gy): 96.0% (90% CI 92.8–99.3)
2-year PFS Arm D: 90.7% (90% CI 86.2–95.4)
Arm B primary threshold: 90% CI lower bound 91.3% exceeded prespecified 85% — met primary endpoint
2-year PFS Arm B (50 Gy): 94.9% (90% CI 91.3–98.6)
2-year PFS Arm C (60 Gy): 96.0% (90% CI 92.8–99.3)
2-year PFS Arm D: 90.7% (90% CI 86.2–95.4)
Arm B primary threshold: 90% CI lower bound 91.3% exceeded prespecified 85% — met primary endpoint
Adverse events
Surgical complications: wound dehiscence 2.8%, pharyngocutaneous fistula 1.1%, hemorrhage 2.0%
RT toxicity: decreased in 50 Gy arm vs 60/66 Gy
Patient-reported (FACT-H&N, MDADI): swallowing/QOL favored lower-dose arms; 50 Gy superior swallowing vs 60 Gy at 6 months
RT toxicity: decreased in 50 Gy arm vs 60/66 Gy
Patient-reported (FACT-H&N, MDADI): swallowing/QOL favored lower-dose arms; 50 Gy superior swallowing vs 60 Gy at 6 months
Conclusions
TOS followed by risk-adapted adjuvant therapy yielded outstanding 2-year PFS (91–97%) in HPV+ OPC with excellent functional preservation, especially de-intensified 50 Gy RT in intermediate-risk patients. E3311 established multi-institutional feasibility of surgical de-escalation and the basis for ongoing phase III surgery vs CRT comparisons.
Key Limitations
Single-arm assignment for low- and high-risk; only intermediate risk randomized. 35-month median follow-up short for late recurrences; long-term OS pending. No direct comparison to definitive CRT — cannot conclude superiority/equivalence to RT-based approaches. Post-surgical pathologic stratification creates selection bias vs pre-treatment allocation. Primary TOS requires surgical credentialing, limiting generalizability.
Clinical Context
Largest prospective multi-institutional experience of transoral surgery in HPV+ OPC. Supports surgery as a valid alternative to definitive CRT, with pathologic staging driving adjuvant de-escalation. Ongoing ECOG-ACRIN EA3161 and ORATOR-2 evaluate surgery vs RT/CRT directly. ASCO and ESMO recognize either definitive CRT or primary surgery ± adjuvant therapy as acceptable options for LA HPV+ OPC.